series-a
Stage
1
Investors
About
MorphImmune develops novel cancer immunotherapies by targeting tumor-specific peptides presented on cancer cells to enhance immune system recognition and destruction of tumors.
Explore MorphImmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.